Global Post-Bariatric Hypoglycemia Market - 2024-2031

Global Post-Bariatric Hypoglycemia Market - 2024-2031

The global post-bariatric hypoglycemia market reached US$ 206.55 million in 2023 and is expected to reach US$ 341.83 million by 2031, growing at a CAGR of 6.5% during the forecast period 2024-2031.

Post-bariatric hypoglycemia (PBH) belongs to a growing complication of bariatric surgery which usually happens after both Roux-en-Y gastric bypass (RYGB) and vertical sleeve gastrectomy (SG). Post-bariatric hypoglycemia usually occurs one to three hours after eating, and its severity can increase after consuming high glycemic index carbohydrates.

The most common way to treat post-bariatric hypoglycemia is to follow the diet recommended by the physician. In acute hypoglycemia, the glucose levels can be restored by administering glucagon or glucose orally. For severe attacks, the glucagon can be given through i.v. route. There are several treatment options available for PBH, which include somatostatin antagonists, GLP-1 receptor antagonists, alpha-glucosidase inhibitors, sodium-glucose cotransporter 2 inhibitors, etc.

Factors such as the rising prevalence of obesity the rising number of bariatric surgeries, and rising research and development activities to discover novel therapies are expected to boost the market growth.

Market Dynamics: Drivers

Increasing Research and Developments for Post-Bariatric Hypoglycemia Treatment

The global post-bariatric hypoglycemia treatment market has been witnessing significant growth due to rising research and development activities. Several therapies have already been tested to be effective for the treatment of PBH, and companies have been investing and developing to develop specific treatment option for PBH. These activities are expected to majorly drive the market growth in the forecast period.

For instance, according to the American Diabetes Association, an article entitled Dasiglucagon Effectively Mitigates Postbariatric Postprandial Hypoglycemia published in March 2022 states that single-dose treatment with either 80 µg or 200 µg dasiglucagon effectively mitigates post-bariatric hypoglycemia in RYGB-operated individuals. While both dasiglucagon doses raised the nadir PG and reduced time in level 1 hypoglycemia, the 200-μg dose completely prevented level 2 hypoglycemia without inducing hyperglycemia. These findings suggest dasiglucagon as a potential new therapeutic for post-bariatric hypoglycemia.

Additionally, in June 2023, Vogenx announced positive results from study VGX 001-011. This phase 2 study was a multicenter, randomized, sequential crossover, single ascending dose study evaluating empagliflozin in patients who suffer from post-bariatric hypoglycemia (PBH). The study examined four doses of mizagliflozin in patients and check the safety, tolerability, and pharmacodynamic response to mizagliflozin. Thus, owing to the above factors the market is expected to boost over the forecast period.

In October 2023, MBX Biosciences. has initiated phase 1/2 clinical trial of MBX 1416 for the treatment of post-bariatric hypoglycemia. MBX 1416 is a long-acting glucagon-like peptide 1 (GLP-1) receptor antagonist. MBX expect topline results by the 1st half of 2024.

Avexitide a glucagon-like peptide 1 (GLP-1) receptor antagonist developed by Eiger BioPharmaceuticals has already received the orphan drug designation in the European Union by the EMA for the treatment of non-insulinoma Pancreatogenous Hypoglycemia Syndrome (NIPHS) and by the US FDA for the treatment of Hyperinsulinemic Hypoglycemia.. Eiger is set to conduct phase 3 clinical trials soon for Avexitide for the treatment of PBH.

Moreover, the rising prevalence of obesity and bariatric surgery is expected to boost the market.

Restraints

Limited treatment options for PBH is expected to restrain the market growth, there is no single approved therapy available for PBH and most of the drugs are used off-lable. Moreover, limited patient population, lack of awareness and non-availability of standardized diagnostic approaches may limit the market growth in the forecast period.

For more details on this report - Request for Sample

Segment Analysis

The global post-bariatric hypoglycemia market is segmented based on drug class, route of administration, distribution channel and region.

Glucosidase inhibitors in the drug class segment accounted for majority of share for the global post-bariatric hypoglycemia

Glucosidase inhibitors, such as acarbose is the most widely prescribed drug for post-bariatric hypoglycemia. This drug slows the carbohydrate metabolism post-prandial, causing the slow release of glucose and preventing hypoglycemia. Although not approved, acarbose is widely prescribed as a first line therapy for PBH. Several studies have proven that acarbose is valid and effective treatment option for PBH.

For instance, in November 2023, an article published in Wiley online library highlights the clincal studies conducted for evaluating the efficacy and safety of acarbose for post-bariatric hypoglycemia. The study stated that acarbose is recommended as a first-line therapeutic option for PBH.

Moreover, acarbose has relatively less side effects which include flatulence, and diarrhoea which diminish over time. The drug is also cost-effective and is widely available worldwide.

Geographical Analysis

North America is expected to dominate the market with a 47.6% share in the global post-bariatric hypoglycemia market

North America is the region with the highest prevalence of obesity and diabetes, due to higher adoption to fast-paced life and unhealthy eating habits. For instance, as per the World Obesity Atlas 2023, in the U.S. nearly 48% of the adult population are obese (BMI>30kg/m2) and by 2035, nearly 58% of adult population would be obese, which is higher than any other nation in the world.

Moreover, North America is well known for its advancements in the healthcare industry. The major countries in the region such as the U.S. and Canada are well known for their investments in healthcare. The favorable yet stringent regulatory policies, favorable environment for research and development activities, higher demand for advanced therapeutics, and high investments in the industry are the factors that are contributing to the region’s dominance. Moreover, the market leaders have stronghold position in the region, and are generating majority of their revenues from here, especially from U.S.

Market Segmentation

By Drug Class
• Glucosidase Inhibitor
• Somatostatin Agonist
• Calcium Ion Influx Inhibitor
• Others

By Route of Administration
• Oral
• Parenteral
• Others

By Distribution Channel
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major players in the post-bariatric hypoglycemia market include Teva Pharmaceuticals, Sun Pharmaceutical Industries Ltd., Wockhardt Ltd., Orchid Chemicals & Pharmaceuticals Ltd., Pfizer, Glenmark Pharmaceuticals, Zee Laboratories Ltd., Bayer AG, Eiger BioPharmaceuticals, and Vogenx among others.

Why Purchase the Report??
• To visualize the global post-bariatric hypoglycemia market segmentation based on drug class, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of post-bariatric hypoglycemia market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global post-bariatric hypoglycemia market report would provide approximately 61 tables, 59 figures, and 187 Pages.

Target Audience 2024
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies